Lasa Supergenerics Ltd. (LASA) AI Stock Analysis

• Market Cap: ₹461.93M
• Dividend Yield: N/A
• Average Volume (3M): 39.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -20.40%
• EPS Growth: -59.20%
• Country: IN
• Employees: 77
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.25
• Shares Outstanding: 50,101,240
• 10 Day Avg. Volume: 9,122
• 30 Day Avg. Volume: 39,131
• PEG Ratio: 0.19
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -32.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ₹9.00 ▼(-20.56% Downside)

The overall stock score is primarily impacted by the company's financial distress, characterized by declining revenues and negative cash flows. Technical indicators further reflect a bearish trend, and poor valuation metrics underscore the company's challenges.

Positive Factors

Manageable Leverage

A moderate debt-to-equity profile provides structural financial flexibility, lowering default risk and preserving access to credit. Over 2-6 months this cushioning helps fund operational adjustments or working capital needs while avoiding aggressive deleveraging that could strain operations.

Equity-Financed Asset Base

A relatively strong equity ratio gives the company a capital cushion against losses and reduces insolvency risk. This durable balance-sheet characteristic supports long-term strategic options—capital raises, restructuring or investments—without immediately increasing leverage.

B2B API Manufacturing Business

Operating in B2B API manufacturing ties the business to steady pharmaceutical production demand and multi-year supplier relationships. Structural need for APIs across therapeutics creates enduring addressable market and repeatable volume opportunities if operational and quality issues are resolved.

Negative Factors

Declining Revenues and Margins

Sustained revenue decline and deteriorating gross margins indicate loss of scale, pricing power, or market share. Over months this weakens the firm’s ability to cover fixed costs, invest in product quality or capability upgrades, and rebuild competitive positioning without sustained turnaround actions.

Negative Operating and Free Cash Flow

Persistent negative operating and free cash flow constrains capital expenditure, raw-material purchasing and debt servicing. Without durable cash generation, the company faces pressure to raise external funding or cut investment, impairing long-term competitiveness and operational continuity.

Persistent Losses and Negative ROE

Negative ROE and ongoing losses erode shareholder value and limit internal capital formation. Over a multi-month horizon this makes financing growth harder, risks dilutive capital raises or asset sales, and signals structural profitability problems that require strategic realignment to fix.

Lasa Supergenerics Ltd. Business Overview & Revenue Model

Company Description

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.

How the Company Makes Money

Lasa Supergenerics Ltd. generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, including APIs and finished formulations. The company operates in a global market, exporting its products to various countries, which significantly contributes to its earnings. Additionally, LASA engages in contract manufacturing for other pharmaceutical companies, which provides a consistent revenue source. Strategic partnerships with multinational corporations and collaborations with research institutions also enhance its revenue potential by expanding its product portfolio and market reach. The company invests in research and development to innovate new products, ensuring a competitive edge and sustained growth in revenue.

Lasa Supergenerics Ltd. Financial Statement Overview

Summary

Lasa Supergenerics Ltd. is experiencing financial distress, with declining revenues, persistent losses, and negative cash flows. The balance sheet shows manageable leverage but the inability to generate profits and positive cash flows poses significant risks.

Income Statement

Lasa Supergenerics Ltd. has faced declining revenues over the past years, with a negative revenue growth rate of approximately -30% from 2021 to 2025. The company's gross profit margin has also deteriorated significantly, indicating shrinking profitability. Furthermore, the net profit margin remains negative, which highlights persistent losses. The EBIT and EBITDA margins show negative trends, further stressing operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, which suggests manageable leverage levels. However, the return on equity has been negative, reflecting the company's inability to generate profits from shareholder equity. The equity ratio remains relatively strong, suggesting a good proportion of assets financed by equity, though the overall financial health is challenged by persistent losses.

Cash Flow

Lasa's cash flow situation is concerning, with a negative free cash flow growth rate and negative operating cash flow in the latest period. The operating cash flow to net income ratio is negative, indicating cash flow issues in relation to net income. While the free cash flow to net income ratio is also negative, it highlights cash flow challenges that could impact future operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.32B	1.42B	1.04B	1.30B	1.37B	2.02B
Gross Profit	318.16M	362.61M	286.95M	-111.88M	427.84M	886.86M
EBITDA	-251.84M	-43.91M	-64.66M	-246.85M	84.12M	469.92M
Net Income	-331.45M	-147.57M	-217.31M	-386.21M	-53.31M	227.78M
Balance Sheet
Total Assets	0.00	1.02B	1.51B	1.64B	2.09B	2.08B
Cash, Cash Equivalents and Short-Term Investments	7.90M	7.90M	14.96M	21.78M	172.17M	44.00M
Total Debt	0.00	21.27M	220.76M	217.70M	201.71M	194.63M
Total Liabilities	-837.13M	178.19M	541.92M	455.69M	512.87M	489.43M
Stockholders Equity	837.13M	837.13M	966.76M	1.18B	1.58B	1.59B
Cash Flow
Free Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	347.24M
Operating Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	413.10M
Investing Cash Flow	0.00	81.52M	-3.98M	111.95M	-29.12M	-35.97M
Financing Cash Flow	0.00	-56.62M	-19.32M	-41.61M	-403.00K	-364.43M

Lasa Supergenerics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 11.33 is above the 20-day moving average (MA) of 9.94, above the 50-day MA of 9.73, and below the 200-day MA of 11.72, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 41.69 is Neutral, neither overbought nor oversold. The STOCH value of 37.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.

Lasa Supergenerics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	63 Neutral	₹269.19M	6.55	―	―	―	―
BIOFILCHEM	62 Neutral	₹469.50M	23.65	―	―	36.76%	433.63%
BALPHARMA	58 Neutral	₹1.07B	13.16	―	1.62%	-9.07%	5.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	48 Neutral	₹1.97B	50.02	―	―	-17.47%	-50.07%
LASA	43 Neutral	₹461.93M	-1.28	―	―	-20.40%	-59.20%